Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
28 Junho 2021 - 9:30AM
Hamilton, Bermuda, June 28, 2021 – Auris Medical
Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing
unmet medical needs through RNA therapeutics, allergy and viral
infection protection, and inner ear therapeutics, today announced
that its affiliate Altamira Medica Ltd. will start the market
roll-out of Bentrio™, its nasal spray for protection against
airborne viruses and allergens, by launching it in Germany.
Bentrio™ will shortly become available through selected online
pharmacies; over the coming months, market coverage will be
expanded progressively through additional distribution channels and
in further countries.
“Following the intense and concerted efforts by
our team and external partners, we are very excited to make Bentrio
available to consumers who are looking to reduce risks from
exposure to airborne viruses and allergens”, commented Ueli
Fankhauser, Altamira Medica’s Head of Commercial. “Despite the
important progress with vaccination programs, the continued
emergence of SARS-CoV-2 variants and lack of full herd immunity
highlight the need for additional means for self-protection such as
Bentrio.”
About
Bentrio™
Bentrio™ (AM-301) is a drug-free nasal spray for
personal protection against airborne viruses and allergens. Upon
application into the nose, Bentrio™ forms a protective gel layer on
the nasal mucosa. This thin film is designed to prevent the contact
of viruses or allergens with cells; in addition, the composition
serves to bind such particles and help with their discharge and to
humidify the nasal mucosa. Together, this is designed to reduce the
risk of upper respiratory tract viral infections and promote
alleviation of allergic symptoms. In human nasal epithelium cells
infected by SARS-CoV-2, Bentrio™ was shown to reduce the infectious
viral load by more than 99% when used for prevention. Further,
Bentrio™ was effective in slowing the growth of the viral titer
when treatment started only 24 or 30 hours after infection. In
allergy, a clinical investigation in a pollen challenge chamber
demonstrated a significant reduction in the main symptoms of
allergic rhinitis with the protective effect setting in rapidly and
lasting for 4 hours.
About Auris Medical
Auris Medical is dedicated to developing
therapeutics that address important unmet medical needs. The
Company is currently active in three areas: the development of RNA
therapeutics for extrahepatic therapeutic targets (OligoPhore™ /
SemaPhore™ platforms; preclinical), nasal sprays for protection
against airborne viruses and allergens (Bentrio™; pre-commercial)
or the treatment of vertigo (AM-125; Phase 2), and the development
of therapeutics for intratympanic treatment of tinnitus or hearing
loss (Keyzilen® and Sonsuvi®, Phase 3). The Company was founded in
2003 and is headquartered in Hamilton, Bermuda with its main
operations in Basel, Switzerland. The shares of Auris Medical
Holding Ltd. trade on the NASDAQ Capital Market under the symbol
“EARS.” The Company will change its name to “Altamira Therapeutics
Ltd.” and its ticker symbol to “CYTO”, subject to approval by a
Special General Meeting of shareholders to be held on July 21,
2021.
Forward-looking Statements
This press release may contain statements that
constitute “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements are
statements other than historical facts and may include statements
that address future operating, financial or business performance or
Auris Medical’s strategies or expectations. In some cases, you can
identify these statements by forward-looking words such as “may”,
“might”, “will”, “should”, “expects”, “plans”, “anticipates”,
“believes”, “estimates”, “predicts”, “projects”, “potential”,
“outlook” or “continue”, or the negative of these terms or other
comparable terminology. Forward-looking statements are based on
management’s current expectations and beliefs and involve
significant risks and uncertainties that could cause actual
results, developments and business decisions to differ materially
from those contemplated by these statements. These risks and
uncertainties include, but are not limited to, the approval and
timing of commercialization of AM-301, Auris Medical’s need for and
ability to raise substantial additional funding to continue the
development of its product candidates, the timing and conduct of
clinical trials of Auris Medical’s product candidates, the clinical
utility of Auris Medical’s product candidates, the timing or
likelihood of regulatory filings and approvals, Auris Medical’s
intellectual property position and Auris Medical’s financial
position, including the impact of any future acquisitions,
dispositions, partnerships, license transactions or changes to
Auris Medical’s capital structure, including future securities
offerings. These risks and uncertainties also include, but are not
limited to, those described under the caption “Risk Factors” in
Auris Medical’s Annual Report on Form 20-F for the year ended
December 31, 2020, and in Auris Medical's other filings with the
SEC, which are available free of charge on the Securities Exchange
Commission's website at: www.sec.gov. Should one or more of these
risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those indicated. All forward-looking statements and all
subsequent written and oral forward-looking statements attributable
to Auris Medical or to persons acting on behalf of Auris Medical
are expressly qualified in their entirety by reference to these
risks and uncertainties. You should not place undue reliance on
forward-looking statements. Forward-looking statements speak only
as of the date they are made, and Auris Medical does not undertake
any obligation to update them in light of new information, future
developments or otherwise, except as may be required under
applicable law.
Investor contact:
investors@aurismedical.com
Auris Medical (NASDAQ:EARS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Auris Medical (NASDAQ:EARS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024